Vascular Closure Device Market Size Is Expected To Reach USD 1.3 Billion By 2024

The Report Vascular Closure Device (VCD) Market Size & Forecast By Product (Active Approximators, Suture-Based Devices, Clip-Based Devices, Passive Approximators, Collagen Plugs, Sealant/Gel-Based Devices, Compression-Assist Devices, External Hemostatic Devices), By End-Use (Acute Care Facilities, Hospitals, Clinics), And Trend Analysis From 2018 – 2024

Global vascular closure devices (VCDs) market is anticipated to reach USD 1.3 billion by 2024, according to a new report by Grand View Research, Inc. Growing popularity of femoral artery cardiac catheterization and high success rate of VCDs for improved patient comfort and shortening of hemostasis time are potential factors for the projected growth of VCDs market over the forecast period. Adoption of VCDs for diagnostic and therapeutic interventions that facilitate endovascular image-guided interventions to detect coronary heart disease are expected to contribute toward the growth of this market throughout the forecast period.

Moreover, ability of VCDs to overcome complications, such as prolonged bed rest and patient discomfort caused by manual compression, is expected to revolutionize the market growth over the forecast period.

Access Research Report of Vascular Closure Device (VCD) Market @ www.grandviewresearch.com/industry-analysis/vascular-closure-device-vcd-market

Further Key Findings from the Study Suggest:

·       VCDs offer three types of products, which includes active approximators, passive approximators, and external hemostatic devices. Out of all three, active approximators dominated the market in 2015 as they shorten the time to ambulation and possess high efficiency rate.

·       Amongst the different end-users of VCDs, acute care facilities accounted for the largest share and are expected to maintain their dominant position over the forecast period. This is attributed to the rising popularity of VCDs in acute care treatment facilities.

·       Asia Pacific is estimated to witness the fastest growth over the forecast period owing to the presence of unmet demands by the hospitals and rising R&D investment in this region.

·       Some key players operating in this industry include Cardinal Health; Abbott Laboratories; COOK; Medtronic; W L. Gore & Associates; Boston Scientific Corporation; Biotronik GMBH & CO.KG; TZ Medical, Inc.; C. R. Bard, Inc.; ST. JUDE MEDICAL; Cardiva Medical, Inc.; Merit Medical Systems, Inc.; ESSENTIAL MEDICAL, INC; and Scion BioMedical.

·       This market is expected to witness lucrative growth owing to high level of competitive rivalry, which translates to high revenue generation in this sector. These prominent players are opting for different strategies to boost their status in this market. Companies are involved in developing novel VCDs and in turn broaden their product portfolios. Acquisition and collaboration with small companies in order to enhance presence is also expected to propel growth in this vertical.

·       For instance, in October 2015, Cardinal Health acquired Johnson & Johnson's Cordis business. Cordis is a leader in manufacturing and marketing of cardiology and endovascular devices. This acquisition was intended to expand Cardinal’s VCD product catalog to reinforce its status in the market.

·       North America dominated the market in 2015, with over 33% of total revenue. The presence of key players in this region, which are primarily involved in marketing and development of innovative VCDs, to facilitate cardiac surgeries can be attributed to the largest share of North America. Demand of products for monitoring of coronary artery disease is also expected to drive growth.

Grand View Research has segmented vascular closure devices market on the basis of product, end use, and region:

Global Vascular Closure Devices Outlook, by Product (Revenue, USD Million, 2013 - 2024)

·         Active Approximators

o    Suture-based Devices

o    Clip-based Devices

·         Passive Approximators

o    Collagen Plugs

o    Sealant- or Gel-based Devices

o    Compression-Assist Devices

·         External Hemostatic Devices

Global Vascular Closure Devices Outlook, by End Use (Revenue, USD Million, 2013 - 2024)

·         Acute Care Facilities

·         Hospitals

·         Clinics

Global Vascular Closure Devices Regional Outlook (Revenue, USD Million, 2013 - 2024)

·         North America

o    U.S.

o    Canada

·         Europe

o    Germany

o    UK

·         Asia Pacific

o    China

o    Japan

·         Latin America

o    Brazil

o    Mexico

o    Argentina

o    Chile

o    Colombia

o    Peru

o    Venezuela

o    Ecuador

o    Panama

o    Costa Rica

·         MEA

o    South Africa

Access Press Release of Vascular Closure Device (VCD) Market @ www.grandviewresearch.com/press-release/global-vascular-closure-device-vcd-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

HPV Testing And Pap Test Market Top Players, Industry Share, Growth, And Forecast To 2024

The Report HPV Testing And Pap Test Market Analysis by Test Type (HPV Test, Pap Test), By Application (Cervical Cancer Screening, Vaginal Cancer Screening), By End-user (Point-of-care, Central laboratories) And Segment Forecasts To 2024

The global human papillomavirus (HPV) testing and pap test market are expected to reach USD 5.6 billion by 2024, according to a new report by Grand View Research Inc.The market is majorly driven by the increasing number of cervical cancer cases, government initiatives, and the heightened awareness amongst women about cervical cancer. For instance, the CDC advocates cervical cancer screening tests for women above the age of 30 as it was found that the cervical cancers are rare in the age group, 20-30 years (2 in 100,000) as compared to the older age groups (16 in 100,000). 

In addition to carrying out awareness campaigns, the government and key industrial players are providing funding to universities for the development of enhanced technologies to facilitate effective screening, which would mitigate the incidence of late-stage cervical cancer. In this direction,in April 2014, the FDA approved the use of the HPV DNA test, also referred to as the Cobas HPV test (Roche Molecular Systems), as a primary screening test. 

A study conducted by the scientists of Hologic, Inc. and University of Pittsburgh Medical Center hasshownthe importance of combined testing (HPV and Pap) stating that the Paptest identifies cellular abnormalities and the HPV test detects suspicious viruses, hence improving the efficiency and providing the best results that are cost-effective and convenient to the patients. 

Access Research Report of HPV Testing And Pap Test Market @ www.grandviewresearch.com/industry-analysis/hpv-testing-pap-test-market

Further key findings from the report suggest:

·       The cervical cancer screening segment dominated the market in 2015 owing to the introduction of advanced technologies for the screening and detection of cervical cancer. For instance, in May 2016,Hologic Inc. determined that HPV and Pap co-testing was the most effective in the screening of cervical cancer.

·       The laboratories segment dominated the HAV and Pap test market in 2015 owing to the increased performance in the diagnosis of cervical cancer cases. As per the CDC statistics, approximately 21.7 million tests were performed in the U.S.; hence,the hospitalssegmentis expected to witnessa rapid growthin the coming years due to the increasing number of diagnostic tests performed in-house and also the availability of advanced technologies.

·       In 2015, North America held the largest share in terms of revenue owing to the continual introduction ofinnovated technologies to improve patient care and diagnosis. In addition, the high number of positive cases being detected,along with the rising death toll (i.e., 2.6 in 1,00,000), has compelled the government to conduct awareness programmes about the early diagnosis and treatment of cervical cancer, which is a key factor for the large market share.

·       In April 2014, the FDA approved the use of the HPV DNA test, also referred to as the Cobas HPV test. Roche introduced a test that detectsthe DNAsequence of cancer-causing high-risk HPVs. It provides information regardingpatients’ risk of developing cervical cancer. The Cobas HPV test is used to specifically identify HPV 16 and HPV 18as well as12 other high-risk HPVs from the cervical cell sample in women older than 25 years of age.

·       AsiaPacific is expected to grow at a high CAGR in the coming years. As per the cancer council, 61% of the Australian women are screened for cervical cancer every two years, out of which around 26% who have been detected throughthe normal Pap test undergo an early re-screening more often than the recommended two years of interval.

·       Some key players in the market are QiagenN. V., Hologic, Inc., Roche Holding AG, Abbott Laboratories, and Becton, Dickinson and Company.These market players are in the process of introducing tests to change the traditional methods of individual HPV and Pap tests and introducenewer techniques or devices to improve the efficiency and convenience.

·       For instance, in February 2016, Quest acquiredClinical Laboratory Partner’s outreach laboratory service business. This acquisition is expected to provide the patients a broader service network with better quality, affordability, and convenience. 

Grand View Research has segmented the global HPV testing and Pap test market on the basis of type, application, end-use, and regions: 

HPV Testing and Pap Test Outlook by Type (Revenue, USD Million, 2013 - 2024)

·         Pap Test

·         HPV Test

HPV Testing and Pap Test Application Outlook (Revenue, USD Million, 2013 - 2024)

·         Cervical Cancer

·         Vaginal Cancer

HPV Testing and Pap Test End-use Outlook (Revenue, USD Million, 2013 - 2024)

·         Point-of-Care

·         Central Laboratories

·         Others

HPV Testing and Pap Test Regional Outlook (Revenue, USD Million, 2013 - 2024)

·         North America

o    U.S.

o    Canada

·         Europe

o    UK

o    Germany

o    Rest of Europe

·         Asia Pacific

o    India

o    Japan

o    China

o    Rest of Asia Pacific

·         Latin America

o    Brazil

o    Rest of Latin America

·         MEA

o    South Africa

Access Press Release of HPV Testing And Pap Test Market @ www.grandviewresearch.com/press-release/global-hpv-test-pap-test-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Automated Dispensing Machine Market Dynamics and Regional Share During 2013-2024

The global automated dispensing machine market was valued at USD 2.9 billion in 2015 and is expected to reach a value of USD 5.5 billion by 2024, according to a new report by Grand View Research, Inc. The growing pressure on the pharmaceuticals due to reimbursement reduction and rapidly growing drug prices leads to inefficient supply chain and inventory management. The growing demand for automated systems, such as RFID cabinet and barcodes, facilitates real-time inventory and stock management, which is one of the pivotal factors expected to drive the market in the coming years.

Furthermore, the increase in global geriatric population and prevalence of various chronic diseases, as well as high rates of hospitalization are some of the factors increasing the burden on pharmacy of hospitals and retail drug stores. Upsurge in number of prescriptions and lack of skilled pharmacist are also few factors expected to boost automation in the medication dispensing system.

There is increasing demand for technologically advanced medication dispensing systems to mitigate long waiting hours for stock replenishment and drug mismanagement, which is one of the crucial factors expected to drive the usage rate of pharmacy automation system, such dispensing, storage, and retrieval. Based on the 2011 ASHP national survey of pharmacy practice in hospital settings, it was stated that approximately 89% of the hospitals are using automated dispensing cabinets and over 10% of the hospitals are using robots.

According to a survey conducted by Society of Actuaries, it was found that measurable medication errors cost USD 20 billion to the U.S. economy, while majority of these errors could have been easily avoided. Increase in medication dispensing errors is a significant factor driving the number of adverse drug reactions, which may lead to severe deterioration of the patient’s health and may also lead to death; this is expected to drive the demand in the coming years. For instance, in the U.S., data published by the Institute of Medicine states that around 7,000 deaths each year can be attributed to medication errors.

Access Research Report of Automated Dispensing Machine Market @ www.grandviewresearch.com/industry-analysis/automated-dispensing-machine-market

Further Key Findings From the Study Suggest:

·       The inpatient segment is the leading application segment and occupies the largest share of 74.4% in 2015. Increasing cases of hospitalization coupled with occurrence of large number of medication errors contribute to the growth of this segment. The outpatient segment is expected to be the fastest growing segment during the forecast period with a CAGR of 8.2%.

·       The hospitals’ segment is the largest, having a share of around 56.1% in 2015. Retail drug stores and pharmacies are expected to be the fastest growing segment during the forecast period with a CAGR of 7.8%.

·       In 2015, the centralized pharmacy segment was the largest operations segment and occupied a share of around 63.4%. The decentralized pharmacy is expected to be the fastest growing segment during the forecast period, with a CAGR of 8.5%.

·       In 2015, North America held majority of market share of over 53.8% in global automated dispensing machines market. Increasing medication errors and rising demand for the overall reduction in operational cost by streamlining medication dispensing processes are few key factors attributed to the regions high market share.

·       Some of the key market players are Omnicell, Inc.; Becton, Dickinson & Co; Baxter; Swisslog; Parata Systems; AmerisourceBergen Corporation. The other key competitors in the market include Pearson Medical Technologies; Script Pro LLC; and Capsa Solutions.

Grand View Research has segmented the automated dispensing machine market by operation, application, end use, and region:

Application outlook (Market revenue in USD Million, 2013 - 2024)

·         Outpatient

·         In-Patient

End-Use outlook (Market revenue in USD Million, 2013 - 2024)

·         Hospitals

·         Retail drug stores and pharmacies

Operation outlook (Market revenue in USD Million, 2013 - 2024)

·         Centralized pharmacies

·         Decentralized pharmacies

Regional outlook (Market revenue in USD Million, 2013 - 2024)

·         North America

o    U.S.

o    Canada

·         Europe

o    UK

o    Germany

·         Asia Pacific

o    Japan

o    China

·         Latin America

o    Brazil

o    Mexico

·         Middle East and Africa

o    South Africa

Access Press Release of Automated Dispensing Machine Market @: www.grandviewresearch.com/press-release/global-automated-dispensing-machine-market

 About Grand View Research

Grand View Research, Inc. is a U.S. based Neurorehabilitation Devices Automated Dispensing Machine Market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer Neurorehabilitation Devices Automated Dispensing Machine Market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com